Reply to “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma”
Clinical and Molecular Hepatology,
Год журнала:
2025,
Номер
31(2), С. e208 - e209
Опубликована: Янв. 7, 2025
Язык: Английский
Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan
The Kaohsiung Journal of Medical Sciences,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 19, 2025
Abstract
An
8‐week
regimen
of
glecaprevir/pibrentasvir
is
recommended
for
treatment‐naïve
patients
with
chronic
hepatitis
C
(CHC).
In
alignment
the
Taiwanese
government's
objective
to
eliminate
by
2025,
this
study
aimed
provide
real‐world
evidence
on
use
in
kidney
disease
(CKD)
using
data
from
Taiwan
Association
Study
Liver
HCV
Registry
(TACR).
CKD
was
defined
an
estimated
glomerular
filtration
rate
(eGFR)
<60
mL/min/1.73
m
2
or
higher
proteinuria
persisting
over
3
months.
Patients
were
categorized
as
having
early
(eGFR
≥45
)
pre‐end‐stage
renal
(pre‐ESRD)
<45
).
Among
1072
who
received
at
least
one
dose
regimen,
1054
had
available
assessing
sustained
virologic
response
12
weeks
posttreatment
(SVR12).
The
overall
SVR12
99.6%,
rates
99.7%
pre‐ESRD
and
99.6%
patients.
Subgroup
analysis
showed
100%
efficacy
genotype
dyslipidemia,
99.5%
diabetes,
99.4%
cardiovascular
disease,
96.9%
a
history
cerebral
vascular
accident,
95.5%
drug
injection
HIV
co‐infection.
Adverse
events
reported
16.8%
patients,
0.8%
experiencing
serious
events,
only
two
cases
treatment‐related.
Renal
function
significantly
improved,
eGFR
increasing
39.2
41.9
.
Early
rise
53.5
57.1,
while
improved
27.1
29.2
SVR12.
concluded
that
highly
effective,
well‐tolerated,
associated
significant
improvement
CHC
both
pre‐ESRD.
Язык: Английский
Reply to comment on “Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program”
Journal of the Formosan Medical Association,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 1, 2025
Язык: Английский